American Clinical Solutions is a leader in providing healthcare providers and medical facilities with accurate urine drug confirmation services for both prescription and illicit narcotics. Using a proprietary method that offers an improved level of detection and accuracy compared to other testing providers, ACS confirms the presence of narcotics and quantifies their levels, helping clinicians develop better, more informed decisions regarding their patients treatment regimens and overall health.
The ACS approach to testing is based on industry standards and tailored according to guidance from our physician partners whose feedback has helped us provide the most comprehensive, highest-quality service and reporting in the field.
How we can help:
By partnering with your practice or facility, ACS will help ensure responsible prescribing and will provide you with recorded data regarding your patients narcotics use as verified and quantified by our state-of-the-art testing methods, affording you extra peace of mind. ACS monitoring can detect the presence of a narcotic drug prior to prescribing and provides an effective avenue for tracking patient compliance throughout the prescription period. Our highly sensitive testing program can enable clinicians to accurately monitor system levels of narcotics to ensure patients follow prescribed guidelines, and can also help clinicians alter medication dosage precisely in response to patient reports or changes in medical status.
Through regular monitoring, you can create a pattern of testing that discourages diversion and helps identify drug seekers and physician shoppers by bridging the gap between patient-reported drug use and actual drug use as reflected by body system medication levels.
Read on to learn more about our staff:
Aixia’s primary responsibilities at American Clinical Solutions (ACS) include the development, optimization, validation, implementation of robust and high throughput liquid chromatography–mass spectrometry methods in compliance with the Clinical Laboratory Improvement Amendments. She applies her deep knowledge, extensive technical skills, and innovative thinking providing guidance to the laboratory operation, troubleshooting, and improvement of efficiency. Recently, she has broadened her knowledge in areas of cannabis testing and nutrients analysis. She works closely with her colleagues to ensure that the goals and objectives of ACS are met.
For over 20 years, she has worked for several of international and domestic organizations across the fields of diagnostic, environmental, pharmaceutical research and development, and clinical toxicology. In Takeda San Diego, she was a representative for drug metabolism and pharmacokinetics and responsible for the bioanalytical aspects of pharmacokinetic, toxicokinetics, pharmacodynamics, structure-activity relationship, drug metabolism, and efficacy studies. Before Takeda, she worked as a scientist at TargeGen Inc., where she provided bioanalytical support to drug discovery programs. Before TargeGen, she honed her skills at Lexicon Genetics Inc., Neurocrine Bioscience Inc., Chugai Pharma USA LLC., Severn Trent Laboratories Inc., and BioMerieux Inc.
- Doctorate degree in Health Science, A.T.Still University, AZ, USA
- Master’s degree in Chemistry, University of Missouri-St. Louis, MO, USA
- Bachelor’s degree in Physical Chemistry and Instrumental Analysis, Tsinghua University, China
- American Society for Mass Spectrometry
- American Association of Bioanalysts
- Clinical laboratory supervisor licensee in State Florida
Xueli Gao earned her Ph.D. in Toxicology from Southern University at Baton Rouge, Louisiana on Dec 2009 and received her Diplomate of American Board of Toxicology (DABT) . She worked on several DARPA and NIH funded projects as postdoc fellow at Department of Chemistry and Department of Ophthalmology, West Virginia University, Morgantown, WV.
Dr. Gao has extensive experiences investigating toxicological and biochemical impacts of pharmaceutical products and toxicants. She worked on several toxicology projects and conducted numerous experiments. Previous projects she worked on include ” Natural Designs for Network Threats” (funded by the Defense Advanced Research Projects Agency, DoD) , “Prediction of Tissue Viability” (funded by Brodie Foundation) and a NIH R01 grant funded project to elucidate in vitro and in vivo effect of proteins(Chaperonin and Phlp ). Dr. Gao also led an independent project focused on understanding the relationship between IGF-1R, p53 and energy metabolism for molecular toxicology applications. Dr. Gao’s research demonstrated the apoptosis cell death mechanisms induced by toxicants.
Parts of Dr. Gao’s research have been published on journals such as Journal of Biological Chemistry, Methods Mol Biol, etc. She also presented her work at many scientific meetings such as Annual Meeting of the Society of Toxicology, International Conference of Alzheimer’s Disease/Parkinson’s Disease, etc.
- Ph.D. in Environmental Toxicology, Southern University, Baton Rouge, LA – Dec 2009
- Dissertation: “Cytotoxicity and Inflammatory Potential of Cholesterol Secoaldehyde: A Cell-based, Mechanistic Study of a Putative Ozone-specific Oxysterol with Implications for Cardiovascular Disease”
- B.S. in Environmental Protection, HuaZhong Agricultural University, Wuhan, China – July 1999
- American Board of Toxicology
- Society of Toxicology(SOT)